RA Capital Management

About

RA Capital Management led Estuary Biotherapeutics' $93 million Series A, announced on 2026-10-16.

The Raise Track Update names RA Capital Management as an investor in: Estuary Biotherapeutics (2026-10-19).

This page is not indexed by search engines yet. It is promoted once it meets the quality gate for investor pages: a description from the firm's own website, a headquarters city and at least two two-sourced rounds on this site.

Funding rounds on RaiseTrack

Sources

Last verified: 2026-10-19

1. https://estuarybio.com/news/estuary-series-a
   Type: company announcement. Accessed 2026-10-19.
   Estuary Biotherapeutics release, 16 October 2026. Names RA Capital Management as the lead of the $93 million Series A.
2. https://www.4biocapital.com/single-post/estuary-biotherapeutics-launches-with-103-million-to-advance-targeted-gene-therapies-for-kidney-dis
   Type: official investor website. Accessed 2026-10-19.
   4BIO Capital post, 16 October 2026. Names RA Capital Management as the lead of the Series A.
3. https://www.fiercebiotech.com/biotech/estuary-emerges-stealth-103m-its-gene-therapies-kidney-disease
   Type: reputable publication. Accessed 2026-10-19.
   Fierce Biotech, labeled Oct 16, 2026, 6:30am. Names RA Capital Management as the lead of the Series A.
4. https://www.biospace.com/deals/estuary-sails-into-kidney-disease-space-with-103m-for-gene-therapies
   Type: reputable publication. Accessed 2026-10-19.
   BioSpace deals article, October 16, 2026. Names RA Capital Management as the lead of the Series A.
5. https://buttondown.com/raisetrack/archive/raise-track-update-2026-10-19/
   Type: other verified public source. Accessed 2026-10-19.
   Raise Track Update for 2026-10-19. Names this firm on Estuary Biotherapeutics' $93 million Series A.